TWI842088B - 人類單羧酸鹽轉運蛋白1抗體及其用途 - Google Patents

人類單羧酸鹽轉運蛋白1抗體及其用途 Download PDF

Info

Publication number
TWI842088B
TWI842088B TW111134587A TW111134587A TWI842088B TW I842088 B TWI842088 B TW I842088B TW 111134587 A TW111134587 A TW 111134587A TW 111134587 A TW111134587 A TW 111134587A TW I842088 B TWI842088 B TW I842088B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
comprises seq
vector
nucleic acid
Prior art date
Application number
TW111134587A
Other languages
English (en)
Chinese (zh)
Other versions
TW202330602A (zh
Inventor
法蘭克 查爾斯 鐸西
喬瑟夫 班傑明 格蘭傑
齊瑞 弗拉基米羅夫娜 盧索瓦
奧利佛 史齊洛德
王薇
Original Assignee
美商伊穆諾米塔博立森發展公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊穆諾米塔博立森發展公司 filed Critical 美商伊穆諾米塔博立森發展公司
Publication of TW202330602A publication Critical patent/TW202330602A/zh
Application granted granted Critical
Publication of TWI842088B publication Critical patent/TWI842088B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111134587A 2021-09-14 2022-09-13 人類單羧酸鹽轉運蛋白1抗體及其用途 TWI842088B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US63/261,177 2021-09-14
US202163272903P 2021-10-28 2021-10-28
US63/272,903 2021-10-28

Publications (2)

Publication Number Publication Date
TW202330602A TW202330602A (zh) 2023-08-01
TWI842088B true TWI842088B (zh) 2024-05-11

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111134587A TWI842088B (zh) 2021-09-14 2022-09-13 人類單羧酸鹽轉運蛋白1抗體及其用途

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201938200A (zh) * 2018-01-05 2019-10-01 美商伊穆奈克斯特股份有限公司 抗mct1抗體及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201938200A (zh) * 2018-01-05 2019-10-01 美商伊穆奈克斯特股份有限公司 抗mct1抗體及其用途

Also Published As

Publication number Publication date
KR20240053656A (ko) 2024-04-24
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
JP7753348B2 (ja) 2025-10-14
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
CA3230072A1 (en) 2023-03-23
DOP2024000049A (es) 2024-06-16
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JOP20240054A1 (ar) 2024-03-13
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US20230340155A1 (en) Antibodies that Specifically Bind PD-1 and Methods of Use
US20210284739A1 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
JP7366747B2 (ja) 血液凝固抗体
TWI790548B (zh) 抗人類cd19抗體
US12304957B2 (en) Anti-CD161 antibodies and uses thereof
CN120757649A (zh) 抗-ctla-4抗体及其用途
AU2019248547A1 (en) Anti-TREM-1 antibodies and uses thereof
US20210047432A1 (en) Therapeutic anti-spla2-gib antibodies and the uses thereof
JP2026004435A (ja) ヒトモノカルボン酸トランスポーター１抗体及びその使用
WO2024200854A1 (en) Allergen binding antibodies suitable for treating tree pollen allergies
JP2022540859A (ja) 新規ｂｓｓｌ抗体
KR20250115437A (ko) Btla 효능제 항체 및 그의 용도
JP2025503707A (ja) ガレクチン－１０抗体
CN118043353A (zh) 人单羧酸转运蛋白1抗体及其用途
CA3169155C (en) Anti-human cd19 antibodies
RU2810094C2 (ru) Прокоагулянтные антитела
WO2024108088A1 (en) Lag-3 and pd-1/lag-3-antibodies
EA052706B1 (ru) Антитела к pd-1
EA040943B1 (ru) Антитела к cd154 и способы их применения